Trials / Recruiting
RecruitingNCT07135544
A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- Sponsor
- Yongjun Chen · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is an exploratory and prospective study, with the research subjects being patients with initially untreated and unresectable biliary tract tumors. The efficacy and safety of the treatment regimen consisting of Adebrelimab monoclonal antibody combined with targeted therapy and systemic chemotherapy were investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adebrelimab combined with the GC regimen and Apatinib | Adebrelimab 1200mg, intravenous infusion, on day 1, repeated every 3 weeks; Gemcitabine 1000mg/m2, on days 1 and 8, every 3 weeks Cisplatin 50mg/m2, on day 1, every 3 weeks Apatinib 250mg, once daily, orally |
Timeline
- Start date
- 2025-08-14
- Primary completion
- 2027-06-30
- Completion
- 2028-12-30
- First posted
- 2025-08-22
- Last updated
- 2025-08-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07135544. Inclusion in this directory is not an endorsement.